CD3(-)CD56(+) non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance

被引:131
作者
Drenou, B
Lamy, T
Amiot, L
Fardel, O
CauletMaugendre, S
Sasportes, M
Diebold, J
LePrise, PY
Fauchet, R
机构
[1] CHRU RENNES,HOP PONTCHAILLOU,SERV HEMATOL CLIN,F-35043 RENNES,FRANCE
[2] CHRU RENNES,HOP PONTCHAILLOU,LAB ANAT PATHOL B,F-35043 RENNES,FRANCE
[3] FAC SCI PHARMACEUT & BIOL,LAB PHYSIOL & HEMATOL,RENNES,FRANCE
[4] HOP ST LOUIS,INSERM,U93,F-75010 PARIS,FRANCE
[5] HOP HOTEL DIEU,ANAT PATHOL LAB,F-75181 PARIS,FRANCE
关键词
D O I
10.1182/blood.V89.8.2966
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
CD56 expression has been reported previously in some non-Hodgkin's lymphoma (NHL) characterization. They principally involve the nascapharynx, are related to Epstein-Barr virus (EBV), and may be classified as either T- or non-T-natural killer (NK) cells according to CD3/T-cell receptor (TCR) status at the genomic or protein level. The present study reports three cases of non-nasal NK-NHL with the following characteristics: an agressive clinical behavior, heterogenous morphological data evoking pleomorphic T-cell malignant lymphoma, a non-T-NK phenotype using flow cytometry, and immunochemistry. The three cases were CD56(+) without membrane expression of specific T markers (CD3, CD5, and TCR), Heterogenous results were observed concerning different antigens: CD2, CD4, CD8, CD16, CD94, CD122, TiAl, perforin, and granzyme B. There was no evidence of detectable clonal TCR gene rearrangement with polymerase chain reaction. No NK activity was detected in the two tested cases, and no relation was found with EBV. Multidrug resistance investigations suggest that agressive clinical findings could be related to MDR1 gene expression as confirmed by MDR1 mRNA detection, MDR1 gene product (Pgp) expression, and a functional multidrug resistance study using rhodamine efflux by flow-cytometry. (C) 1997 by The American Society of Hematology.
引用
收藏
页码:2966 / 2974
页数:9
相关论文
共 51 条
[1]   HIGH EXPRESSION OF CD56 (N-CAM) IN A PATIENT WITH CUTANEOUS CD4-POSITIVE LYMPHOMA [J].
ADACHI, M ;
MAEDA, K ;
TAKEKAWA, M ;
HINODA, Y ;
IMAI, K ;
SUGIYAMA, S ;
YACHI, A .
AMERICAN JOURNAL OF HEMATOLOGY, 1994, 47 (04) :278-282
[2]  
[Anonymous], 1989, SYNTHETIC OLIGONUCLE
[3]  
BRODY JP, 1995, CANCER, V75, P2474, DOI 10.1002/1097-0142(19950515)75:10<2474::AID-CNCR2820751013>3.0.CO
[4]  
2-Y
[5]   EXPRESSION AND ACTIVITY OF P-GLYCOPROTEIN, A MULTIDRUG EFFLUX PUMP, IN HUMAN HEMATOPOIETIC STEM-CELLS [J].
CHAUDHARY, PM ;
RONINSON, IB .
CELL, 1991, 66 (01) :85-94
[6]   DIVERSE MULTIDRUG-RESISTANCE-MODIFICATION AGENTS INHIBIT CYTOLYTIC ACTIVITY OF NATURAL-KILLER-CELLS [J].
CHONG, ASF ;
MARKHAM, PN ;
GEBEL, HM ;
BINES, SD ;
COON, JS .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 36 (02) :133-139
[7]   MULTIDRUG RESISTANCE ACTIVITY IN HUMAN-LYMPHOCYTES [J].
COON, JS ;
WANG, YZ ;
BINES, SD ;
MARKHAM, PN ;
CHONG, ASF ;
GEBEL, HM .
HUMAN IMMUNOLOGY, 1991, 32 (02) :134-140
[8]   DETECTION OF P-GLYCOPROTEIN ACTIVITY ON NORMAL AND LEUKEMIC CD34+ CELLS [J].
DRENOU, B ;
FARDEL, O ;
AMIOT, L ;
FAUCHET, R .
LEUKEMIA RESEARCH, 1993, 17 (12) :1031-1035
[9]   CD5(-) CD56(+) T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas [J].
Emile, JF ;
Boulland, ML ;
Haioun, C ;
Kanavaros, P ;
Petrella, T ;
DelfauLarue, MH ;
Bensussan, A ;
Farcet, JP ;
Gaulard, P .
BLOOD, 1996, 87 (04) :1466-1473
[10]  
Fukuda J, 1994, Rinsho Ketsueki, V35, P588